IQVIA Reports $3.7 Billion in Q1 Revenue

IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, has reported its first-quarter 2024 results. The company's revenue for the first quarter was $3,737 million, marking a 2.3% increase on a reported basis and a 2.9% increase at constant currency compared to the same period in 2023.

In terms of segment performance, the Technology & Analytics Solutions (TAS) revenue increased by 0.6% on a reported basis and 1.0% at constant currency, reaching $1,453 million. Meanwhile, Research & Development Solutions (R&DS) revenue grew by 3.4% on a reported basis and 3.8% at constant currency, amounting to $2,095 million. Excluding the impact of pass-throughs, R&DS revenue experienced a substantial 6.9% reported basis growth. Contract Sales & Medical Solutions (CSMS) revenue also saw a notable increase, rising by 3.8% on a reported basis and 7.1% at constant currency to $189 million.

The company's R&D Solutions quarterly bookings were reported at an impressive $2.6 billion, representing a book-to-bill ratio of 1.23x for the quarter. The R&DS contracted backlog, including reimbursed expenses, stood at $30.1 billion as of March 31, 2024, reflecting a significant 7.9% year-over-year growth and an 8.3% increase at constant currency. Furthermore, IQVIA anticipates approximately $7.7 billion of this backlog to convert to revenue in the next twelve months.

In the first quarter of 2024, IQVIA's GAAP net income was $288 million, with GAAP diluted earnings per share at $1.56. Adjusted net income was $468 million, resulting in adjusted diluted earnings per share of $2.54. The adjusted EBITDA also demonstrated growth, reaching $862 million, marking a 1.3% increase year-over-year.

Looking at the financial position, as of March 31, 2024, IQVIA reported cash and cash equivalents of $1,444 million and debt of $13,536 million, resulting in a net debt of $12,092 million. The net leverage ratio was reported at 3.38x trailing twelve-month adjusted EBITDA. Additionally, the company's operating cash flow for the first quarter amounted to $522 million, with free cash flow at $377 million.

For the full-year 2024 guidance, IQVIA reaffirms its revenue guidance on a constant currency basis, with expected revenue in the range of $15,325 million to $15,575 million on a reported basis. This guidance represents a year-over-year foreign exchange headwind of approximately 100 basis points. The company also reaffirms its full-year adjusted EBITDA guidance of $3,700 million to $3,800 million, representing growth of 3.7 to 6.5% and its full-year adjusted diluted EPS guidance of $10.95 to $11.25, reflecting an increase of 7.4 to 10.3% year-over-year.

Today the company's shares have moved -2.2% to a price of $227.83. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.